Illumina, Inc. vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Illumina, Inc. trades at $182.09 (market cap $27.94B), while YieldMax MSTR Option Income Strategy ETF trades at $13.44. The key difference: Illumina, Inc. is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | MSTY | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $194.33 | $108.80 |
52-Week Low | $91.00 | $11.55 |
Enterprise Value | $29.33B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
MSTY trades at $13.12, up 2.34% today, but remains in a bearish technical trend with significant price depreciation year-to-date. The ETF generates high weekly dividend distributions, but these are offset by substantial capital erosion, as highlighted by financial media. Key technical indicators signal selling pressure, with moving averages and oscillators predominantly bearish or neutral.
The outlook is cautious due to structural risks in the covered-call strategy capping upside potential while exposing investors to full downside. High distributions may not be sustainable if funded by return of capital. Investor sentiment is negative, with media reports emphasizing total return losses outweighing dividend income.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →